Risk Adapted Treatment of Myelofibrosis: a Focus on Quality-of-life

Risk Adapted Treatment of Myelofibrosis: a Focus on Quality-of-life is organized by Rockpointe Corporation.,Release Date: Sep 22, 2022,Expiration Date: Sep 22, 2023,Description:,Myelofibrosis is a rare myeloproliferative neoplasm associated with poor outcomes. Because the early stages of the disease are associated with minimal symptoms, most patients are diagnosed with advanced disease. In these patients, overall survival can be short and the risk of transformation to leukemia is high. To improve patient outcomes, it is important that high-risk patients with advanced diseases are identified early and receive appropriate treatment. While historically there have been limited treatment options for advanced myelofibrosis, several novel JAK inhibitors have been approved in the past decade that significantly improve disease symptoms and overall survival, improving patient quality of life. However, the use of these agents can be challenging, both in determining the optimal treatment selection, identifying when to switch therapies, and minimizing the impact of disease symptoms and treatment-related adverse events on patient quality of life.,This activity, Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life, will provide hematologists and oncologists with important information on the role of risk stratification in guiding treatment selection, efficacy, and safety data for current and emerging myelofibrosis therapies, and strategies for integrating these agents into clinical practice in a way that prolongs survival, minimizes adverse events, and improves patient quality-of-life.,Educational Objectives:,At the conclusion of this education, participants should be able to:,• Use guideline-recommended scoring systems to develop risk-informed treatment plans for patients with myelofibrosis,• Integrate the latest clinical trial evidence into the selection and sequencing of treatments for patients with advanced myelofibrosis,• Develop strategies to improve patient quality of life by minimizing disease symptoms and treatment-related toxicities,• Communicate with patients regarding their disease, symptoms, and treatment options